OvaScience planning follow-on

Fertility company OvaScience Inc. (NASDAQ:OVAS) proposed late Monday a follow-on underwritten by Leerink. OvaScience is developing Augment, which is intended to increase the success of in vitro fertilization (IVF). The Augment process involves isolating mitochondria from a woman's egg precursor cells and injecting them into her egg along with a sperm cell to improve the success rate of IVF.

This year, OvaScience is conducting a "limited commercial launch" of Augment in international IVF clinics. The company said it also plans to meet with FDA to determine the path forward for the technology in the U.S. Last year, OvaScience suspended a U.S. trial of Augment after FDA said the company needed an IND (see BioCentury Extra, Sept. 11, 2013). ...